Cosmos Health Inc. revenue
Cosmos Health Inc.'s revenue was $65.3m in fiscal 2025, up 19.9% on the year before. Since fiscal 2013 ($902,369) it has grown at a compound 42.9% a year. Over the last twelve months it was $73.7m.
Revenue history
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 8 | 1 | 7 | 30 | 37 | 40 | 55 | 56 | 50 | 53 | 54 | 65 | 74 |
| Growth on the year before | — | +746.6% | −93.0% | +>999% | +344.3% | +23.6% | +7.0% | +39.6% | +1.5% | −10.5% | +6.0% | +2.0% | +19.9% | — |
| Gross profit | — | 8 | 0 | 1 | 2 | 2 | 4 | 8 | 8 | 6 | 4 | 4 | 8 | 8 |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Wholesale | $59.3M | 90.9% | ▲ 15.0% |
| Nutraceuticals and Pharmaceuticals | $4.3M | 6.5% | ▲ 116.7% |
| Pharmamanufacturing | $1.7M | 2.6% | ▲ 95.2% |
| Other | $1,228 | 0.0% | — |
From Cosmos Health Inc.'s 10-K filed April 15, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Cosmos Health Inc. | $73.7m | 33.8% | 14.8% |
| Cellyan Biotechnology Co., Ltd | $13.4m | -33.9% | — |
| 111, Inc. | $1.75bn | -12.7% | — |
| Henry Schein | $13.60bn | 6.5% | 2.6% |
| Cencora | $332.77bn | 5.1% | 9.4% |
| McKesson | $410.98bn | 8.8% | 13.1% |
Compare with peers
- Cellyan Biotechnology Co., Ltd revenue
- 111, Inc. revenue
- Henry Schein revenue
- Cencora revenue
- McKesson revenue
Head to head: COSM vs HKPDCOSM vs YICOSM vs HSIC
More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies